This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer’s disease


Grossberg, George, Meng, Xiangyi, Olin, Jason T.


American Journal Of Alzheimer's Disease And Other Dementias, Volume: 26, No.: 1, Pages.: 65-71

Year of Publication



Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer’s disease (AD).; Methods: Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm(2)]), rivastigmine capsules (6 mg twice daily), or placebo, and impact on activities of daily living (ADLs) was assessed utilizing 3 subscales: basic, high-level function, and autonomy.; Results: At week 24, both rivastigmine groups demonstrated significantly superior performance in Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score versus placebo (rivastigmine patch, P = .013; capsules, P = .039). Overall, both rivastigmine formulations provided benefits in ADL subscales. For basic ADLs, rivastigmine capsules performed significantly better than placebo (P = .012). For high-level function ADLs, rivastigmine patch performed better than placebo (P = .056). For autonomy ADLs, rivastigmine patch performed significantly better than placebo (P = .017).; Conclusion: Rivastigmine patches and capsules provide significant effects in both total and subscale ADLs in patients with probable AD.;

Bibtex Citation

@article{Grossberg_2011, doi = {10.1177/1533317510391240}, url = {}, year = 2011, month = {jan}, publisher = {{SAGE} Publications}, volume = {26}, number = {1}, pages = {65--71}, author = {G. Grossberg and Xiangyi Meng and J. T. Olin}, title = {Impact of Rivastigmine Patch and Capsules on Activities of Daily Living in Alzheimer{textquotesingle}s Disease}, journal = {American Journal of Alzheimer{textquotesingle}s Disease and Other Dementias} }


activities of daily living, administration & dosage, administration oral, aged, aged, 80 and over, alzheimer disease, capsules, double-blind method, drug therapy, female, humans, male, middle aged, neuroprotective agents, phenylcarbamates, prospective studies, psychology, rivastigmine, therapeutic use, time factors, transdermal patch, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime